Related Experiment Videos
Controlled trial with chloroquine diphosphate in systemic lupus erythematosus
I M Meinão1, E I Sato, L E Andrade
1Division of Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil.
Lupus
|June 1, 1996
Summary
Chloroquine diphosphate (CDP) effectively reduces corticosteroid needs and prevents flares in systemic lupus erythematosus (SLE) patients. This study highlights antimalarials
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Antimalarials are established for articular and cutaneous lupus manifestations.
- Their role in systemic lupus erythematosus (SLE) systemic features requires further evaluation.
Purpose of the Study:
- To assess chloroquine diphosphate (CDP) efficacy in preventing SLE flares.
- To evaluate CDP's ability to reduce corticosteroid maintenance dosage in non-life-threatening SLE.
Main Methods:
- A 12-month, double-blind, placebo-controlled trial involving 24 SLE patients without severe manifestations.
- Monthly clinical and laboratory assessments, with prednisone dose adjustments.
- Flare defined as SLEDAI score increase ≥3; dose reduction as ≥50% decrease without flare.
Main Results:
- CDP group showed significantly lower prednisone doses at 4, 6, and 12 months compared to placebo.
- SLEDAI scores were consistently higher in the placebo group, significantly at 4 months.
- Flare episodes occurred in 2 CDP patients versus 10 placebo patients; reactivation risk was 4.6x higher with placebo.
Conclusions:
- CDP (250 mg/day) effectively prevents SLE exacerbations and reduces prednisone requirements.
- CDP aids in better disease control for non-life-threatening SLE.
- Antimalarials may have broader applications in SLE management beyond skin and joint symptoms.